use
dna
immun
approach
deliv
protect
antigen
yersinia
pesti
pesti
success
previous
report
studi
current
studi
gene
design
v
two
wellstudi
virul
factor
serv
main
target
vaccin
develop
alter
explor
addit
option
hope
improv
protect
immun
dna
vaccin
express
two
antigen
compar
wild
type
v
gene
dna
vaccin
use
codon
optim
v
gene
sequenc
effect
improv
antigen
express
titer
antiv
antibodi
respons
surviv
mucos
lethal
challeng
dna
vaccin
remov
ntermin
hydrophob
region
abl
improv
protect
immun
howev
ad
mammalian
signal
peptid
sequenc
actual
led
reduc
protect
despit
induc
slightli
higher
antibodi
respons
gene
fuse
gene
code
yscf
newli
confirm
partial
protect
antigen
pesti
produc
dna
vaccin
express
fuse
yscf
antigen
one
design
particular
yscf
fuse
downstream
sequenc
produc
better
protect
separ
yscf
dna
vaccin
suggest
potenti
synergist
effect
two
antigen
find
studi
indic
multipl
approach
optim
protect
immun
plagu
dna
vaccin
importantli
proper
antigen
engin
produc
optim
antigen
gene
insert
dna
vaccin
clearli
play
major
role
futur
design
wide
rang
dna
vaccin
plagu
caus
bacterium
yersinia
pesti
pesti
still
remain
potenti
public
health
threat
mani
part
world
also
seriou
concern
potenti
bioterror
agent
two
main
form
plagu
bubon
plagu
result
transmiss
bacteria
via
bite
infect
flea
pneumon
plagu
caus
subsequ
spread
bacteria
lung
pneumon
plagu
also
transmiss
person
person
via
airbon
transmiss
almost
fatal
left
untreat
although
vaccin
use
prevent
infect
pesti
number
kill
wholecel
kwc
vaccin
live
attenu
vaccin
develop
year
variou
shortcom
drawback
limit
wide
use
prevent
plagu
human
two
pesti
protein
fraction
capsular
protein
lcrv
v
protein
known
protect
antigen
last
decad
subunit
vaccin
base
v
recombin
protein
shown
immunogen
protect
variou
anim
studi
plagu
challeng
subunit
vaccin
compris
recombin
v
protein
shown
immunogen
phase
clinic
trial
level
protect
antibodi
respons
impress
may
persist
extend
period
search
addit
protect
antigen
achiev
limit
progress
third
protect
antigen
yscf
recent
report
sever
independ
studi
level
protect
partial
test
lethal
challeng
studi
anim
model
recent
dna
vaccin
emerg
novel
approach
immun
begin
show
promis
sign
util
human
previou
studi
includ
demonstr
dna
vaccin
express
v
antigen
abl
elicit
antigenspecif
antibodi
respons
protect
anim
lethal
plagu
challeng
via
mucos
rout
time
experi
accumul
studi
dna
vaccin
pathogen
indic
efficaci
dna
vaccin
improv
prototyp
design
origin
gene
sequenc
pathogen
antigen
directli
clone
dna
vaccin
vector
sever
wellestablish
strategi
includ
antigen
engin
signal
peptid
select
codon
usag
optim
affect
optim
express
antigen
encod
dna
vaccin
one
uniqu
consider
dna
vaccin
express
bacteri
antigen
codon
usag
dna
vaccin
develop
human
applic
high
level
express
mammalian
cell
requir
howev
express
protein
code
bacteri
gene
mammalian
cell
hamper
codon
usag
bacteri
gene
may
optim
protein
express
mammalian
cell
previou
studi
shown
codon
optim
effect
improv
antigen
express
andor
immunogen
dna
vaccin
wide
rang
viral
pathogen
human
immunodefici
viru
type
influenza
papillomaviru
hpv
limit
studi
bacteri
pathogen
anthrax
tetanu
current
studi
three
approach
taken
improv
plagu
dna
vaccin
first
dna
vaccin
express
v
antigen
previou
report
show
codon
optim
v
dna
vaccin
effect
wild
type
v
gene
dna
vaccin
elicit
antiv
antibodi
mice
howev
attempt
made
determin
whether
vaccin
abl
increas
level
protect
current
studi
synthes
new
codon
optim
dna
sequenc
code
pesti
v
antigen
synonym
codon
altern
base
wild
type
lcrv
gene
sequenc
mous
studi
conduct
examin
whether
codon
optim
improv
ultim
protect
even
effect
level
antibodi
respons
second
differ
optim
approach
employ
antigen
current
studi
recombin
protein
immunogen
previous
develop
dna
vaccin
previou
studi
also
demonstr
ad
leader
sequenc
human
tissu
plasminogen
activ
tpa
abl
improv
immunogen
dna
vaccin
howev
studi
show
simpl
remov
put
leader
sequenc
protect
modifi
insert
use
signalbear
polypeptid
semliki
forest
viru
order
reconcil
differ
combin
design
two
studi
use
leader
tpa
studi
significantli
test
final
protect
outcom
addit
antibodi
respons
biomark
evalu
differ
dna
vaccin
previou
studi
shown
although
newli
confirm
protect
antigen
yscfbase
dna
vaccin
abl
elicit
protect
mucos
lethal
challeng
mous
model
protect
level
elicit
either
two
antigen
low
compar
elicit
v
antigenbas
dna
vaccin
therefor
final
approach
current
studi
fuse
two
gene
one
larg
dna
vaccin
insert
see
whether
yscf
antigen
work
synergist
fusion
protein
design
pesti
strain
kim
prepar
grow
inocula
h
tryptos
blood
agar
base
difco
supplement
mm
cacl
without
addit
blood
bacteria
remov
plate
inocul
loop
resuspend
injectiongrad
pb
bacteria
count
suspens
correl
optic
densiti
od
number
bacteria
final
inocula
confirm
coloni
count
codon
optim
full
length
lcrv
gene
sequenc
pesti
kim
strain
design
mcvector
comput
softwar
accord
codon
prefer
human
gene
shown
tabl
chemic
synthes
geneart
inc
germani
wild
type
lcrv
gene
amplifi
pfu
dna
polymeras
strategen
ca
virul
plasmid
pesti
primer
previou
describ
either
wild
type
codon
optim
lcrv
gene
individu
clone
dna
vaccin
vector
psti
bamhi
site
downstream
cytomegaloviru
cmv
immedi
earli
ie
promot
adjac
intron
final
dna
plasmid
prepar
use
mega
dna
purif
kit
qiagen
valencia
ca
vitro
express
anim
immun
studi
hydrophob
region
nterminu
protein
may
repres
put
natur
signal
peptid
four
version
dna
vaccin
construct
without
remov
ntermin
hydrophob
region
wild
type
dna
vaccin
construct
previous
describ
gene
follow
remov
natur
signal
peptid
amplifi
primer
pair
tabl
respect
gene
insert
directli
subclon
previous
describ
dna
vaccin
vector
pstibamhi
clone
site
nheibamhi
clone
site
immedi
downstream
tpa
leader
sequenc
infram
subclon
insert
two
dna
vaccin
express
yscf
fusion
protein
construct
tpa
leader
sequenc
gene
fragment
delet
stop
codon
amplifi
use
primer
yscf
gene
amplifi
primer
two
fragment
ligat
togeth
induc
sali
site
linker
valasp
junction
yscf
gene
delet
stop
codon
amplifi
primer
gene
amplifi
two
fragment
ligat
togeth
induc
spei
site
linker
alaalathrserglygli
junction
dna
vaccin
construct
verifi
restrict
digest
gene
sequenc
suffici
amount
dna
vaccin
prepar
qiagen
mega
plasmid
purif
kit
valencia
ca
vitro
transfect
anim
immun
applic
express
dna
vaccin
construct
examin
transient
transfect
cell
transfect
done
cell
approxim
confluenc
dish
calcium
phosphat
coprecipit
use
plasmid
dna
per
dish
supernat
celllys
harvest
hour
transfect
v
antigen
express
confirm
western
blot
system
pool
mous
sera
specif
v
antigen
use
detect
antibodi
homemad
quantit
elisa
use
measur
amount
v
antigen
produc
v
dna
vaccin
construct
known
amount
recombin
v
antigen
use
establish
standard
curv
femal
balbc
mice
week
old
purchas
tacon
farm
germantown
ny
hous
anim
facil
manag
depart
anim
medicin
univers
massachusett
medic
school
accord
iacuc
approv
protocol
anim
receiv
three
biweekli
dna
immun
week
biorad
helio
gene
gun
biorad
hercul
ca
boost
week
one
week
prior
pesti
challeng
v
dna
vaccin
empti
vector
plasmid
coat
onto
gold
bead
dnamg
gold
shot
deliv
dna
total
six
nonoverlap
shot
deliv
mous
shave
abdomin
skin
anim
anesthet
serum
sampl
collect
week
prior
challeng
mous
sera
test
v
igg
antibodi
respons
microtit
plate
coat
recombin
v
antigen
pb
overnight
wash
five
time
wash
buffer
pb
ph
triton
block
done
milkwhey
block
buffer
hour
room
temperatur
remov
block
buffer
anoth
five
wash
serial
dilut
mous
sera
ad
incub
hour
plate
wash
five
time
incub
biotinyl
antimous
igg
vector
laboratori
burlingam
ca
dilut
hour
follow
wash
horseradish
peroxidaseconjug
streptavidin
vector
laboratori
dilut
ad
incub
hour
final
wash
fresh
tmb
substrat
sigma
ad
per
well
incub
min
reaction
stop
ad
h
optic
densiti
od
plate
measur
nm
plagu
antigen
transient
express
supernat
cell
lysat
subject
denatur
sdspage
blot
onto
pvdf
membran
biorad
block
done
iblock
tropix
bedford
v
mous
sera
use
detect
antibodi
dilut
incub
minut
subsequ
membran
wash
block
buffer
react
apconjug
goat
antirabbit
tropix
dilut
final
wash
westernlight
substrat
appli
membran
minut
membran
dri
kodak
film
expos
membran
develop
xomat
processor
challeng
perform
intranas
instil
salin
contain
lethal
dose
pesti
kim
strain
nostril
ketamineanesthet
mice
method
lead
rapid
infect
lethal
nonimmun
mice
day
ld
median
lethal
dose
challeng
model
determin
previou
studi
data
shown
cfu
equal
approxim
ld
ld
respect
individu
mice
challeng
two
week
fourth
immun
observ
twice
daili
monitor
morbid
mortal
studi
conduct
biosafeti
level
contain
facil
depart
anim
medicin
umm
statist
analysi
done
student
ttest
signific
differ
regard
antibodi
respons
fisher
exact
test
percent
protect
explor
whether
codon
usag
lcrv
gene
caus
differ
v
antigen
express
andor
immunogenicti
design
chemic
synthes
codon
optim
sequenc
lcrv
gene
synthet
lcrv
gene
codon
origin
wild
type
lcrv
gene
altern
new
codon
prefer
express
mammalian
cell
deviat
strict
adher
mammalian
cellpref
codon
made
avoid
chang
certain
restrict
enzym
site
subclon
use
potenti
inhibitori
effect
secondari
rna
structur
figur
show
codon
usag
wild
type
codon
optim
lcrv
gene
result
codon
optim
domin
codon
use
amino
acid
dna
sequenc
analysi
show
gc
content
codon
optim
lcrv
gene
wild
type
lcrv
gene
wild
type
wt
codon
optim
opt
lcrv
gene
individu
subclon
vector
describ
materi
method
evalu
rel
potenc
wild
type
codon
optim
lcrv
code
sequenc
compar
v
antigen
express
two
type
v
dna
vaccin
transient
transfect
cell
shown
figur
v
antigen
express
high
level
cell
lysat
codon
optim
v
dna
vaccin
vopt
compar
wild
type
v
dna
vaccin
base
western
blot
analysi
express
level
vopt
increas
determin
elisa
fig
sinc
leader
sequenc
either
wtv
vopt
dna
construct
v
antigen
mostli
express
intracellularli
transfect
cell
lysat
predict
order
analyz
whether
high
level
vitro
express
v
antigen
could
translat
stronger
immun
respons
vivo
group
balbc
mice
per
group
immun
either
wtv
vopt
dna
vaccin
addit
empti
dna
vector
neg
control
gene
gun
week
antibodi
respons
measur
elisa
sera
pool
anim
group
differ
time
point
consist
vitro
express
result
codon
optim
v
dna
vaccin
induc
quicker
higher
antibodi
respons
wtv
dna
vaccin
fig
serum
vspecif
igg
respons
induc
vopt
detect
even
first
dna
immun
contrast
antibodi
respons
induc
wtv
dna
vaccin
detect
second
dna
immun
rel
low
level
peaklevel
vantigen
specif
igg
titer
measur
individu
mous
sera
within
group
mean
titer
group
compar
two
v
dna
vaccin
fig
week
one
week
th
dna
immun
mean
vspecif
igg
titer
vopt
dna
vaccin
group
higher
observ
wtv
immun
group
analysi
show
wtv
vopt
elicit
antibodi
respons
ratio
respons
greater
fig
mice
immun
describ
dna
vaccin
challeng
week
anim
inocul
highli
lethal
challeng
pesti
kim
strain
cfu
equival
intranas
rout
anim
receiv
dna
vector
control
quickli
develop
easili
observ
sign
infect
rough
coat
hunch
huddl
postur
shiver
labor
breath
lethargi
within
first
hour
mice
die
within
day
fig
partial
protect
gener
wtv
dna
vaccin
mice
surviv
two
week
challeng
fig
full
protect
achiev
vopt
dna
vaccin
mice
anim
surviv
two
week
studi
period
fig
nonprotect
mice
exhibit
sign
sick
shortli
challeng
usual
die
within
day
obviou
sick
observ
among
surviv
anim
differ
surviv
wtv
vopt
statist
signific
p
four
version
antigen
insert
design
dna
vaccin
current
studi
fig
previou
studi
demonstr
dna
vaccin
full
length
gene
without
tpa
leader
sequenc
upstream
full
length
gene
could
produc
partial
protect
intranas
challeng
pesti
mice
although
addit
tpa
leader
full
length
sequenc
abl
achiev
detect
secret
protein
supernat
transient
transfect
cell
fig
moder
increas
antibodi
respons
fig
dna
vaccin
effect
gener
better
protect
pesti
challeng
full
length
dna
vaccin
level
protect
anim
immun
dna
vaccin
significantli
reduc
surviv
intranas
challeng
cfu
ld
dna
vaccin
abl
protect
mice
receiv
intranas
challeng
fig
p
two
addit
dna
insert
test
current
studi
remov
short
segment
gene
sequenc
nterminu
code
hydrophob
amino
acid
residu
clear
whether
segment
similar
function
put
leader
sequenc
usual
associ
mani
mammalian
protein
two
version
modifi
gene
without
ntermin
hydrophob
segment
produc
one
start
codon
atg
extra
leader
sequenc
human
tissu
plasminogen
activ
tpa
protein
fig
transient
express
demonstr
version
dna
vaccin
abl
express
antigen
transfect
cell
lysat
also
supernat
fig
dna
vaccin
induc
good
level
antibodi
respons
rang
significantli
differ
induc
dna
vaccin
fig
howev
dna
vaccin
induc
clear
protect
benefit
surviv
intranas
challeng
fig
dna
less
effect
elicit
protect
dna
vaccin
still
achiev
level
protect
surviv
dna
vaccin
fig
combin
protect
result
four
dna
vaccin
made
clear
ad
tpa
leader
either
wild
type
ntermin
hydrophob
segment
remov
counterproduct
elicit
lower
level
protect
counterpart
without
tpa
leader
due
small
differ
surviv
rate
statist
signific
group
fisher
exact
test
although
group
alreadi
includ
mice
per
group
yscf
recent
identifi
third
protect
antigen
plagu
small
molecular
weight
kda
without
put
leader
sequenc
demonstr
previou
studi
yscf
like
could
produc
partial
protect
plagu
mice
effect
power
v
antigen
order
determin
whether
synergist
effect
fusion
protein
contain
yscf
antigen
compon
construct
design
two
version
dna
vaccin
express
yscf
antigen
fig
depend
whether
yscf
antigen
fuse
cterminu
antigen
call
respect
dna
vaccin
produc
clone
one
two
insert
dna
vaccin
vector
downstream
tpa
leader
sequenc
express
yscf
compon
two
fuse
antigen
dna
vaccin
examin
transient
transfect
cell
follow
western
blot
analysi
fusion
antigen
dna
vaccin
express
antigen
well
probe
rabbit
serum
fig
higher
overal
protein
express
improv
secret
supernat
fig
similarli
separ
western
blot
analysi
antiyscf
antibodi
abl
identifi
fusion
protein
antigen
antigen
alon
data
shown
immunogen
two
novel
yscf
fusion
protein
antigen
studi
dna
vaccin
induc
similar
titer
antigenspecif
antibodi
respons
elicit
dna
vaccin
fig
immun
sera
also
recogn
antigen
equal
strength
titer
similar
elicit
dna
vaccin
fig
control
dna
vaccin
express
either
yscf
antigen
could
elicit
antibodi
respons
one
antigen
fig
result
indic
yscf
fusion
dna
vaccin
immunogen
elicit
antibodi
yscf
antigen
immun
anim
subsequ
challeng
cfu
pesti
intranas
inocul
protect
achiev
group
immun
dna
vaccin
fig
better
group
immun
either
alon
surviv
alon
surviv
dna
vaccin
interestingli
mice
surviv
group
receiv
fusion
antigen
dna
vaccin
dna
vaccin
group
lower
dna
vaccin
group
fig
mock
dna
immun
group
receiv
empti
dna
vector
without
pesti
antigen
insert
quickli
develop
easili
observ
sign
sick
die
within
first
day
postchalleng
fig
current
report
use
differ
approach
improv
immunogen
protect
efficaci
plagu
dna
vaccin
express
v
alon
fuse
yscf
result
show
immunogen
bacteri
antigen
improv
use
either
wellestablish
approach
codon
optim
less
studi
approach
antigen
engin
pesti
genom
harbor
three
plasmid
necessari
full
virul
bacterium
besid
chromosom
base
analysi
gene
code
sequenc
equal
larger
bp
overal
gc
content
whole
pesti
genom
synonym
codon
usag
pattern
gene
differ
gene
express
level
strongli
relat
frequenc
gc
third
posit
synonym
codon
usag
sequenc
analysi
pesti
gene
code
v
protein
lcrv
part
low
calcium
respons
lcr
plasmid
show
gc
content
codon
usag
directli
link
prefer
trna
usag
given
cell
type
conceiv
codon
optim
lcrv
gene
import
high
level
express
bacteri
protein
mammalian
cell
howev
previou
report
codon
optim
v
gene
base
murin
codon
prefer
make
differ
dna
vaccin
vector
test
mice
peak
antiv
antibodi
titer
measur
result
current
studi
show
codon
optim
effect
elicit
higher
antibodi
respons
also
improv
protect
compar
wild
type
v
genebas
dna
vaccin
sever
differ
two
studi
first
exact
level
codon
chang
may
differ
howev
sinc
sequenc
inform
avail
previou
studi
hard
compar
exact
sequenc
differ
two
studi
studi
also
made
sure
minim
sequenc
chang
may
gener
inhibitori
secondari
rna
structur
known
whether
similar
analysi
incorpor
previou
studi
quit
unusu
previou
report
one
group
mice
immun
codon
optim
v
gene
dna
vaccin
wors
immun
respons
wild
type
v
gene
dna
vaccin
appear
chang
codon
optim
v
gene
neg
effect
otherwis
immunogen
wild
type
v
gene
second
studi
approach
differ
two
report
studi
conduct
garmori
et
al
comparison
codon
optim
wild
type
v
dna
vaccin
done
mice
use
intramuscular
im
immun
mice
requir
five
im
immun
posit
antiv
antibodi
titer
could
detect
howev
previou
current
studi
strong
posit
antiv
igg
respons
easili
detect
within
two
dna
immun
deliv
gene
gun
shown
recent
physic
dna
deliveri
method
gene
gun
electropor
much
effect
intramuscular
needl
inject
method
overal
antibodi
level
low
previou
report
protein
boost
given
order
detect
differ
codon
optim
wild
type
v
gene
use
prime
immun
may
bring
variabl
final
measur
final
current
studi
protect
result
challeng
studi
provid
definit
evid
support
surviv
benefit
codon
optim
v
dna
vaccin
previou
studi
test
differ
challeng
studi
vaccin
formul
differ
codon
usag
differ
optim
approach
employ
antigen
current
studi
kda
protein
consid
import
essenti
virul
factor
uniqu
pesti
reason
mutant
bacteri
strain
abolish
virul
pesti
lead
delay
onset
diseas
anim
model
recombin
protein
immunogen
dna
vaccin
previou
studi
also
demonstr
addit
leader
sequenc
human
tissu
plasminogen
activ
tpa
front
entir
origin
code
sequenc
abl
improv
immunogen
dna
vaccin
studi
anoth
group
show
remov
put
leader
sequenc
code
sequenc
protect
ad
signalbear
polypeptid
semliki
forest
viru
order
reconcil
differ
combin
design
two
studi
use
leader
tpa
studi
leader
sequenc
tpa
shown
multipl
dna
vaccin
studi
produc
secret
downstream
protein
mammalian
express
system
result
immunogen
mani
dna
vaccin
tpa
leader
also
improv
shown
higher
antibodi
respons
includ
envelop
protein
lcrv
protein
pesti
origin
gene
short
hydrophob
segment
nterminu
may
serv
put
leader
sequenc
bacteri
protein
test
effect
ad
tpa
leader
gene
without
remov
put
leader
ad
tpa
leader
type
gene
abl
increas
secret
protein
shown
increas
detect
cultur
supernat
improv
level
antiv
igg
respons
howev
protect
result
show
addit
tpa
leader
led
lower
protect
compar
counterpart
without
tpa
leader
case
either
pair
pair
ie
remov
put
leader
make
addit
tpa
leader
effect
find
confirm
data
protect
level
keep
origin
put
leader
replac
put
leader
new
tpa
leader
similar
worst
among
four
dna
vaccin
design
basic
two
leader
one
tpa
plu
put
leader
effect
design
without
ntermin
leader
sequenc
clear
leaderless
protect
given
find
design
lead
highest
igg
respons
futur
studi
analyz
addit
bacteri
protein
understand
whether
bacteri
protein
uniqu
sequenc
may
affect
express
mammalian
system
importantli
function
conform
elicit
protect
immun
respons
knowledg
import
dna
vaccin
also
recombin
proteinbas
bacteri
vaccin
start
enter
vaccin
develop
pipelin
recent
year
dna
vaccin
studi
present
current
report
certainli
use
valuabl
tool
subunitbas
vaccin
studi
bacteria
vaccin
take
advantag
larg
number
protein
associ
type
pathogen
includ
multipl
antigen
one
vaccin
formul
improv
efficaci
vaccin
minim
escap
vaccineinduc
protect
howev
technic
polyval
subunitbas
vaccin
challeng
cost
technic
complex
associ
product
multipl
protect
vaccin
compon
past
fusion
protein
propos
minim
issu
associ
physic
separ
bival
v
protein
vaccin
current
report
test
concept
make
yscf
fusion
antigen
test
dna
immun
result
indic
dna
vaccin
express
yscf
fusion
protein
could
induc
antigenspecif
antibodi
respons
yscf
antigen
two
version
fusion
antigen
produc
either
upstream
yscf
yscf
upstream
immunogen
evidenc
abil
gener
similar
level
antigenspecif
antibodi
respons
howev
improv
protect
observ
yscf
fuse
downstream
protein
design
fusion
antigen
design
reduc
protect
dna
vaccin
use
baselin
control
protect
studi
use
fusion
antigen
previou
studi
demonstr
yscf
dimer
form
monom
form
protect
therefor
includ
yscf
monom
control
current
studi
even
dimer
form
yscf
protect
level
partial
protect
intranas
challeng
pesti
also
interest
observ
design
much
higher
level
secret
antigen
could
induc
better
protect
immun
latter
antigen
alon
includ
found
protect
leader
sequenc
requir
high
level
secret
examin
vitro
assay
therefor
may
total
surpris
mainli
intracellularli
express
fusion
protein
protect
easili
secret
fusion
protein
howev
find
along
sever
result
present
current
report
point
import
antigen
engin
next
phase
dna
vaccin
research
past
given
genebas
natur
dna
vaccin
optim
dna
vaccin
vector
deliveri
dna
vaccin
main
focu
research
conduct
find
chang
code
sequenc
significantli
affect
immunogen
also
protect
bring
attent
design
antigen
insert
may
affect
wide
rang
consider
includ
antigen
conform
antigen
express
posttransl
antigen
modif
ultim
fate
antigen
process
present
vivo
remain
larg
unknown
dna
vaccin
result
report
use
pesti
protein
model
antigen
make
antigen
engin
first
step
complic
process
previous
note
comparison
codon
usag
frequenc
amino
acid
wild
type
codon
optim
lcrv
gene
vspecif
immun
protect
induc
v
dna
vaccin
tempor
vspecif
antibodi
respons
grouppool
sera
serum
dilut
arrow
indic
timepoint
dna
immun
b
peak
level
vspecif
antibodi
titer
th
dna
immun
data
show
mean
titer
standard
deviat
balbc
mice
group
statist
differ
indic
vopt
wtv
dna
immun
group
c
ratio
vopt
wtv
dna
immun
mice
peak
antibodi
respons
vivo
protect
mice
immun
differ
v
dna
vaccin
indic
balbc
mice
challeng
lethal
dose
cfu
pesti
intranas
inocul
one
week
th
dna
immun
percent
surviv
group
balb
c
mice
shown
indic
signific
differ
p
surviv
rate
vopt
wtv
dna
immun
group
igg
respons
induc
differ
dna
vaccin
balbc
mice
igg
titer
measur
elisa
result
shown
mean
titer
group
mice
per
group
th
dna
immun
b
protect
mice
immun
differ
dna
vaccin
balbc
mice
challeng
lethal
dose
cfu
pesti
intranas
inocul
one
week
dna
immun
cumul
surviv
curv
plot
show
protect
group
indic
vector
control
group
includ
neg
control
schemat
diagram
yscf
fusion
gene
insert
dna
vaccin
number
indic
amino
acid
posit
black
open
grey
box
repres
tpalead
sequenc
yscf
gene
respect
b
westernblot
analysi
fusion
protein
use
supernat
lysat
l
cell
transient
transfect
differ
dna
vaccin
empti
vector
dna
vaccin
vector
use
posit
neg
control
mous
sera
use
detect
antibodi
dilut
